C5 and atypical hemolytic-uremic syndrome: Treatment with eculizumab, a complement blocker, that blocks cleavage of C5 and thus prevents C5a and C5b-9 generation, has reduced thrombosis rates in patients with paroxysmal nocturnal hematuria (48) and atypical hemolytic uremic syndrome (49).